BeiGene, Ltd. (NASDAQ:BGNE) Short Interest Update

BeiGene, Ltd. (NASDAQ:BGNE) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,090,000 shares, a decrease of 27.8% from the October 15th total of 1,510,000 shares. Based on an average trading volume of 319,500 shares, the short-interest ratio is presently 3.4 days.

BeiGene Stock Up 0.9 %

NASDAQ BGNE opened at $195.45 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The stock has a market capitalization of $19.04 billion, a P/E ratio of -23.72 and a beta of 0.63. The stock has a fifty day moving average of $212.91 and a 200-day moving average of $181.72.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative return on equity of 25.15% and a negative net margin of 25.94%. The business’s revenue for the quarter was up 28.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.01 earnings per share. On average, equities research analysts forecast that BeiGene will post -5 EPS for the current year.

Insider Buying and Selling at BeiGene

In other BeiGene news, COO Xiaobin Wu sold 5,556 shares of BeiGene stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $189.65, for a total value of $1,053,695.40. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, COO Xiaobin Wu sold 5,556 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John Oyler sold 6,175 shares of the stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. Insiders sold 23,070 shares of company stock worth $4,901,050 over the last ninety days. Company insiders own 7.43% of the company’s stock.

Hedge Funds Weigh In On BeiGene

Large investors have recently bought and sold shares of the business. Capital International Investors boosted its stake in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after acquiring an additional 727,556 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of BeiGene during the second quarter worth $54,412,000. M&G Plc acquired a new position in shares of BeiGene in the 1st quarter valued at $29,649,000. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of BeiGene by 160.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock valued at $50,706,000 after buying an additional 138,978 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of BeiGene by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after buying an additional 117,905 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on BGNE shares. TD Cowen increased their target price on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup lifted their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. JMP Securities initiated coverage on shares of BeiGene in a report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price on the stock. StockNews.com upgraded shares of BeiGene from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $247.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.